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Abstract: 
Brain AVMs are abnormal connections between arteries and veins. Endovascular glue embolization 
with NBCA is an accepted form of treatment. The reported complication rates of NBCA embolization 
varies widely from 2-15%, and timing of polymerization plays a major role.  
Polymerization time was measured for mixtures of lipiodol/NBCA of 50/50, 70/30, 60/40. The 
influence of pH, temperature and presence of biological catalysts on polymerization time was 
investigated in-vivo. PVA-C, silicone and endothelium surfaces were compared. High-speed video 
analysis of glue injection through a microcatheter was performed.  
Polymerization rate increases with pH and temperature. A hydrophilic surface such as PVA-C better 
mimics endothelium. Biological substrates including endothelium and blood products dramatically 
increase the polymerization rate. Characterization of coaxial flow shows dripping to jetting 
transition with significant wall effect.  
The determinants of NBCA polymerization rate are multifactorial and dependent mainly upon the 
presence of biological substrates coupled with flow-related wall interaction. 
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General Introduction/Background 
Natural history of AVMs: 
Brain arteriovenous malformations (AVMs) are abnormal connections between arteries and veins 
without an intervening capillary bed.[1, 2] The prevalence of brain AVMs in the general population 
is not precisely known. Previous studies reported numbers that range from 2 to 20 per 100,000 
people.[1-3] Some AVMs are asymptomatic while others are symptomatic and cause brain 
hemorrhage (50%), seizures (40%), neurologic deficits (12%) and chronic headache (14%).[4] 
Asymptomatic AVMs are discovered either incidentally during neurological imaging for unrelated 
reasons or at the time of autopsy. Asymptomatic AVMs are more common with an estimated 
prevalence of approximately 10-20 per 100,000 people.[1, 3] Symptomatic AVMs, on the other hand, 
occur with a lower frequency of approximately 1-3 per 100,000 people.[2, 3]  
Approximately half of all patients with symptomatic AVMs present with an intracerebral 
hemorrhage.[4-6] In the pediatric population this number is even higher, approaching 80%.[7] Based 
on natural history studies, the annual risk of hemorrhage from an AVM is around 2-4% per year.[6, 
8-11] The biggest risk factor associated with AVM hemorrhage appears to be a history of prior 
hemorrhage. AVMs that have ruptured have a higher re-rupture rate in the first year of 6-13%, and 
the hemorrhage rate returns to baseline thereafter at 4% per year or lower.[4, 5, 8, 9, 11] Other 
factors that increase the risk of hemorrhage include deep venous drainage, existence of associated 
aneurysms, venous stenosis and deep/infratentorial location.[6, 8-11] AVM nidus size is an 
inconsistent risk factor, with some studies showing smaller AVMs associated with higher risk of 
hemorrhage while other studies showing larger AVMs to be more risky.[9, 11] Some studies looking 
at AVM feeding artery pressure suggest that smaller AVMs are associated with higher feeder pressure, 
offering a potential explanation for their higher risk of rupture.[12, 13] Larger AVMs, on the other 
hand, tend to have higher flow rates and potentially expose the fragile “arterialized” veins to higher 
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hemodynamic stresses, thereby providing an alternate explanation for their propensity to 
rupture.[11, 13, 14]  
Brain AVM rupture is a rare cause of intracerebral hemorrhage, accounting for 1.4-2% of all 
hemorrhagic strokes;[1, 10, 15] however, in the young adult population (age 18 to 45), it accounts 
for 25-35% of all hemorrhagic strokes.[6, 16] Hemorrhage is arguably the most serious problem 
caused by AVMs, and it can have potentially life-threatening consequences for some patients. 
Mortality after hemorrhage from a brain AVM is reported to be around 10% while residual major 
disability occurs in 20%–30% of patients.[6, 8-11]  
Treatment of AVMs:  
Brain AVMs can be treated with open surgery, endovascular embolization, or radiation. All these 
treatment modalities share a common goal, which is to obliterate the abnormal connections between 
the feeding arteries and draining veins.[17, 18] Surgery provides the most direct approach, while 
endovascular therapy attempts to disrupt blood flow to the nidus from within the feeding vessels. 
Radiation, in the form of stereotactic radiosurgery (SRS), induces endothelial proliferation and 
results in progressive nidus occlusion over time. Unlike surgery or embolization which exerts its 
effect immediately, cure from SRS typically occurs slowly, exhibiting a plateau at 3-5 years out (up to 
8 years in select patients). The AVM cure rate from SRS varies widely depending on a number 
variables. In carefully selected patients, it could be as high as 70-80%.[19, 20] Interestingly, 
endovascular embolization prior to SRS decreases the rate of occlusion at 3 years to approximately 
40%.[19]  
Symptomatic AVMs (hemorrhage or progressive neurologic deficit) are typically treated with surgery 
and/or endovascular therapy. Endovascular embolization using liquid embolic agents is an accepted 
form of treatment of brain AVMs.[18, 21] It is most often used as an adjunct to surgery to reduce 
perioperative blood loss, although it is sufficient as a stand-alone treatment in approximately 5-10% 
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of cases.[18, 22] Previous authors have identified certain AVM characteristics associated with higher 
likelihood of embolization cure such as: small AVM nidus size, less than 3 feeders and superficial 
feeder/AVM location.[22] When these characteristics are used to screen patients, the cure rate of 
brain AVMs with embolization alone is higher, ranging from 20% to over 50%.[21-26] This variability 
is likely related to selection bias and to the lack of rigorous definition of embolization goals – i.e. 
curative intent versus preoperative devascularization.[22]  
Two liquid embolic agents have found widespread use in the clinical setting: N-butyl cyanoacrylate 
(NBCA) and Ethylene vinyl alcohol copolymer (EVOH, known commercially as Onyx®). These are the 
only FDA approved liquid embolic agents for neuro-interventional use. The reported complication 
rate with NBCA embolization varies between 2% to 15%.[21, 23, 25] Hartmann et al. reported in their 
series of 233 patients treated with NBCA embolization an overall complication rate of 14% and major 
disability/mortality rate of 3%.[21] Some authors have suggested that most of the complications that 
occur during embolization with NBCA are related to polymerization rate. [18, 21] A rate that is too 
fast may cause proximal feeder artery occlusion. Glue could then reflux back into normal upstream 
vessels, causing stroke. Conversely, a rate that is too slow could cause the glue to occlude the draining 
vein, or embolize to the lung.[27] Premature venous drainage occlusion may raise the AVM intranidal 
pressure and trigger intracranial hemorrhage.[24, 28, 29] 
The scientific literature reports a wide range of polymerization rates with large discrepancies 
between in-vivo and in-vitro results.[18, 30, 31] Furthermore, the interaction between glue and 
vessel surface, as well as the presence of biologic catalysts are poorly understood. Despite its clinical 
use for over 4 decades (FDA approved in 2000 with clinical use dating almost 3 decades prior), there 
is still incomplete understanding of NBCA polymerization and injection behavior.[18] This has 
resulted in large variability amongst authors with respect to glue concentration (typically modified 
by altering glue/Lipiodol or glue/acetic-acid ratio) and the injection technique (sandwich, wedge or 
full-column technique) used for NBCA embolization procedures.[18, 21]   
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Onyx (Covidien, USA) is becoming increasingly popular (FDA approved in 2003) amongst many 
neuro-interventionalists due to its perceived margin of safety during injection. Onyx has a higher 
viscosity and slower polymerization rate (more accurately, polymer condensation rate). Therefore, 
injection can be made over a longer period of time than NBCA with time scales measured in minutes 
rather than seconds.[18] However, the actual treatment morbidity and mortality is not significantly 
lower compared to NBCA. Despite the lack of good quality randomized controlled trials, numerous 
case series have reported overall complication rates between 1% and 17%.[22, 26, 32, 33] Katsaridis 
et al. reported in their series of 101 AVMs treated with Onyx embolization an overall complication 
rate of 11% and mortality rate of 3%.[26]   
Onyx is unsuitable for high-flow lesions (e.g. AVMs with large fistulous components) because 
polymerization must occur over a relatively short period of time. In addition, embolization with Onyx 
in lenticulostriate or thalamoperforating arteries is associated with a high rate of complication (as 
much as 50%[24]) and can only be accomplished with NBCA. The amount of NBCA operator 
experience has gradually decreased since the introduction of Onyx. In situations where NBCA is the 
only option for AVM embolization, the treatment risk for patients is further exacerbated given the 
incomplete understanding of NBCA polymerization behavior.  
Liquid embolic agent chemistry: 
NBCA belongs to the family of cyanoacrylate glues which were first synthesized in 1949 and first 
reported as a tissue adhesive about 10 years later.[34] Figure i. illustrates the chemical formula of 
various types of cyanoacrylate monomers with different side chain groups (methyl, ethyl, butyl and 
octyl).[35] The length of side chain determines the polymerization rate, with longer side chains 
associated with a slower reaction rate. The final polymer formed also becomes more flexible and 
more resistant to biological degradation as the side chain length increases. For biological use, butyl 
(NBCA, Histoacryl® – Braun, Germany) or octyl (Dermabond® - Ethicon, USA) sidechains offers better 
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mechanical matching of tissues and avoids the brittle polymer chains formed by methyl or ethyl 
(Krazy Glue®) side chains. Cyanoacrylates decompose in the body via hydrolysis and methyl-  or 
ethyl-cyanoacrylates produce toxic break down products such as formaldehyde as well as eliciting 
strong inflammatory reactions. Because of this, methyl-  and ethyl-cyanoacrylates are not used for 
biological purposes.[34]   
 
 
                
 
 
Polymerization of cyanoacrylate monomers may occur via one of three mechanisms: anionic, 
zwitterionic or free radical. Figure ii. shows the polymerization mechanism of the anionic pathway. 
Of the three, the first two are strongly favored in-vivo due to the presence of hydroxide or amine 
groups in the body to initiate the polymerization reaction.[34, 36] These groups also serve as binding 
sites on proteins that allow strong bonds to form with cyanoacrylates.[37]  
Figure ii. Polymerization mechanism of cyanoacrylate 
monomers via the anionic pathway. The presence of 
an anion such as OH- initiates the reaction and results 
in chain polymerization. 
Figure i. Chemical formula of various types of 
cyanoacrylate monomers. Increasing side chain length 
decreases polymerization rate and tissue toxicity. 
Adapted from Kyle et al. 
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NBCA has a rapid polymerization time and good tissue adherence, making it an effective agent for 
sealing off abnormal vessel connections. However, this very property also makes it difficult to control 
as described in the previous section. Additionally, the catheter tip may become glued to the vessel 
wall, forcing the physician to leave a piece of the catheter behind. The ideal situation is for NBCA to 
polymerize in the AVM nidus itself, thereby arresting all flow into the AVM.  
Pure NBCA reacts extremely fast in-vivo and is almost never used except in pediatric Vein of Galen 
malformations.[18] To decrease NBCA polymerization rate, various compounds can be added to 
create glue mixtures. Acetic acid has been used as a polymerization retardant to slow down the 
reaction mainly by decreasing the pH and the availability of anions such as OH-. Currently, most 
centers use Lipiodol (ethiodized poppyseed oil) as both a radio-opaque agent and as a polymerization 
retardant. However, the addition of lipiodol to NBCA slightly raises the mixture’s viscosity, requiring 
greater injection force by the operator.[38]  In the earlier years, tantalum powder was added as a 
radio-opaque agent to allow visualization under fluoroscopy. However, some authors reported 
spontaneous polymerization of NBCA-tantalum mixture when it was left unused for 15 minutes or 
more.[31] 
Typical mixtures of Lipiodol/NBCA encountered clinically are 50/50, 60/40, 70/30 
(volume/volume). Increasing the amount of lipidol increases the polymerization time and conversely 
decreases the polymerization rate. However, choosing the right formulation, injection rate and glue 
volume is an imprecise science. To date, studies looking at the behavior of NBCA under physiological 
conditions have been rather crude. Most interventionalists rely on experience and look at the 
cerebral angiogram for clues. They determine the NBCA formulation based on nidus size, rate of 
contrast clearance, number of feeding arteries and draining veins. The injection rate is a bit more 
difficult to quantify, and most of the time it is an experienced “best guess”. In the full column 
technique, once the glue is injected the catheter is quickly withdrawn to prevent adhesion of the tip 
to the vessel wall.  
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For comparison, the properties of Onyx will be briefly outlined below but will not be the focus of this 
study. Onyx consists of a suspension of EVOH polymer in dimethyl sulfoxide (DMSO) with tantalum 
powder added for radio-opacity.[18] Figure iii. below shows the chemical formula of Onyx. It should 
be noted that the polymer chains in Onyx suspension are already formed. Polymerization does not 
actually occur since the suspension does not contain monomer units. Instead, upon injection, DMSO 
quickly diffuses out of the suspension and EVOH precipitates into a soft rubbery mass in an aqueous 
environment, resulting in vessel occlusion. The occlusion time measured during injection reflects 
precipitation time rather than polymerization time. Onyx injections occur over the timespan of 
minutes and may extend up to half-hour or more. In fact, a slow injection rate is encouraged since 
prior animal work demonstrated that an overly vigorous injection can results in vessel tissue 
dissolution by DMSO with potentially catastrophic consequences. Time is needed for DMSO to 
dissolve and dilute into the bloodstream and surrounding interstitial tissue. Due to its slower rate of 
action compared to NBCA, complications can arise in high-flow AVMs where Onyx embolizes to the 
lungs. Although not an adhesive polymer, Onyx can also cause mechanical interference with the 
microcatheter, resulting in difficult removal similar to NBCA.  
 
  
Figure iii. Chemical formula of Onyx, with variable (x) number of vinyl alcohol groups and (y) number of ethyl 
groups. The polymer chains dissolve well in DMSO and remain in suspension. In an aqueous environment such 
as blood, the polymer chains are relatively hydrophobic and interact with each other strongly (via hydrogen 
bond and van de Waals’ forces), precipitating out of solution to form a soft rubbery mass. 
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Characteristics and factors that influence embolization – a brief analysis: 
Characteristics: during embolization in the angiography suite there are several observable 
characteristics intrinsic to the AVM which can be summarized as morphologic versus hemodynamic 
(Table i). 
Table i. Morphologic and hemodynamic characteristics that influence embolization 
Morphologic Hemodynamic 
- AVM nidus size 
- Number of feeders/draining veins 
- Size of feeders/draining veins 
- Physical location of nidus, feeders, and 
draining veins (e.g. supra- vs. 
infratentorial, superficial vs. deep)  
- Nidus morphology: fistulous, 
plexiform, mixed, single vs multiple 
compartments, etc. 
- Presence of venous varices/ectasias 
- Presence of nidal/prenidal aneurysms 
Non-invasive 
- Flow rate: estimated with frame-
counting (at ≥4fps) or TCD 
- Regional variability in flow rate in 
nidus/feeders/draining veins 
(angiography or TCD) 
Invasive 
- Feeder/vein pressure 
- Feeder flow velocity (direct Doppler 
insonation) 
 
The morphologic characteristics tend to have an association with the likelihood of complete nidus 
occlusion and complication rate as described in the previous section. The hemodynamic 
characteristics predominantly provide indirect flow rate information. Together with morphologic 
characteristics, they provide an indication of how quickly the glue needs to harden. Pressure 
measurements may provide an indication of the risk of hemorrhage with partial embolization or 
early vein occlusion, although the association is even less clear than the association with risk of 
spontaneous hemorrhage.[12] Intravascular pressures are also observed to rise as the feeder and its 
supplied nidus approach complete occlusion.[39]  
Factors: In the angiography suite there appear to be a few modifiable factors that surgeons or neuro-
interventionalists can control during the embolization of AVMs. These include: 
- The distance between the microcatheter tip and the AVM nidus 
- Glue mixture 
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- The power of the injection 
How each of these factors influence embolization will be outlined below. 
Distance between microcatheter tip and nidus 
The longer the distance between the microcatheter tip and the nidus, the longer the time the glue 
needs to remain liquid. This information will need to be considered together with the estimated flow 
velocity (typically observed using frame-counting) to provide a time estimate. The location of the 
catheter tip may vary based on the injection technique. For example, a wedge technique would 
require the catheter tip to be within the nidus and “wedged” against the wall. In this case, the distance 
is essentially zero. In the full-column technique, the catheter tip will be parked in the feeder a short 
distance away from the nidus. In addition to technique, there are often limitations as to how far the 
catheter can be navigated. A very tortuous and/or distal feeder (e.g. distal anterior cerebral artery) 
will limit how close the microcatheter tip can be advanced to the nidus. 
Glue mixture 
Changes in the NBCA/Lipiodol mixture changes the rate of polymerization. Interventionalists alter 
this ratio based on how much time it is determined that the glue must remain liquid. This is described 
in the paragraph above. The ultimate goal is to have as much of the glue polymerize within the nidus 
as possible without premature occlusion of the feeding artery or draining vein. Currently, there is no 
good data that accurately reflects the in-vivo polymerization time of various NBCA/Lipiodol mixtures 
to help guide interventionalists. One of the objectives of this project is to generate such data to aid 
interventionalists during embolization. 
Since polymerization is a continuous process, polymerization times should be calculated for each 
glue concentration at three different time points: t0, t50 and tc. t0 is the time to onset of polymerization, 
first observed when the surface of the glue droplet opacifies and begins to deform. t50 is the time to 
achieve a 50% change in height of the glue droplet (or 50% reduction in diameter in any direction). 
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tc is the time to complete polymerization (or over 95% polymerization based on continuous video 
observation). Distinction between the three time points is important because NBCA probably does 
not need to reach tc for a significant change in AVM feeder to occur; it only need to be firm enough to 
occlude the feeder.  
Injection power 
This factor includes a number of components. Power = Work/Time and Work = Force x Distance. 
Looking at the relationship between a glue syringe and the interventionalist’s hand, force is applied 
to the plunger which makes it travel a certain distance. This distance is directly related to the volume 
of glue injected. The amount of force needed to do this will depend on the total resistance of the 
syringe-microcatheter combination, the flow rate, as well as any additional downstream resistance 
from feeding artery pressure or partially formed glue casts. The time it takes to perform the injection 
will depend on both the injection velocity (how quickly the glue is pushed into the nidus) and the 
total volume of glue used (more glue = more time pushing the syringe). Injection power captures all 
of these variables into a single value, potentially allowing for objective quantification of operator-
dependent injection parameters. 
Taking a closer look at the amount of force exerted, the syringe in the operator’s hand can be pushed 
with a certain amount of force. The greater the force, the higher the flow rate. The overall resistance 
of the system can be simplified to three factors: 
1. Resistance from the syringe (different for 1cc vs 3cc) 
2. Microcatheter Pouiselle flow resistance (see formula below) 
3. Additional resistance from connectors and geometry changes 
The size of the syringe has a direct effect on pressure (P) in the catheter since P = F/A, and for a given 
force (F) applied by the operator, a smaller syringe will have a smaller cross-sectional area (A), 
resulting in a greater pressure. This pressure will then cause greater volumetric flow rate (Q) based 
on the Pouiselle equation: 
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∆𝑃 =
8𝜇𝐿
𝜋𝑟4
𝑄 
Eq.1 Pouiselle flow equation: L=length of catheter, μ=dynamic viscosity, r=radius of catheter 
If we examine the system in series the resistance acts in series. Starting with the applied pressure Pa 
by the operator, there will be a pressure drop across the plunger due to plunger friction ∆Pp. Next, 
there will be a pressure drop across the chamber of the syringe due to fluid resistance ∆Ps, which is 
probably negligible but will be included in the initial analysis and expressed as a loss coefficient Cs. 
There will be a pressure drop across the syringe opening due to orifice effect (vena contracta, an 
example is shown below in Figure iv.) ∆Po, which can be presented as a loss coefficient Co.  
 
 
There will be a pressure drop across the connector hub of the microcatheter ∆Pc, which can also be 
represented as a loss coefficient Cc. The pressure drop within the microcatheter ∆Pm is outlined below 
and the final outlet pressure at the very tip of the microcatheter is Pf. If we add the pressure drops all 
together, assuming the syringe is pushed slowly and the velocity inside is negligible, the total 
pressure drop across the system can expressed as:  
∆𝑃𝑠𝑦𝑠 = 𝑃𝑎 − 𝑃𝑓 
∆𝑃𝑠𝑦𝑠 = ∆𝑃𝑝 + ∆𝑃𝑠 + ∆𝑃𝑜 + ∆𝑃𝑐 + ∆𝑃𝑚 
Eq.2 Overall pressure drop across the system 
 
 
Figure iv. Example of vena contracta 
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For ∆𝑃𝑝  if we imagine the plunger as a cylinder with radius rp and thickness t the pressure exerted 
by the friction force of the plunger rubber against the syringe wall can be calculated as follows: 
  ∆𝑃𝑝 =  
𝑓∗𝐹𝑛
𝜋𝑟𝑝2𝑡
 
Eq.3 Pressure loss due to friction of the rubber plunger against syringe wall, equation variables are outlined below. 
 
Where f* is the coefficient of friction (either static or kinetic depending on the plunger motion), and 
Fn is the radial normal force exerted by the plunger against the syringe wall. The coefficient of friction 
will change depending on whether the injection is just starting where fs should be used versus if the 
injection is under way where fk should be used instead. Practically speaking, it might be difficult to 
ascertain f* ands Fn accurately, so the final value of ∆𝑃𝑝will probably need to be measured empirically. 
The remaining pressure drop terms can be expressed as: 
 ∆𝑃𝑠 =  𝐶𝑠𝑄 
∆𝑃𝑜 =  𝐶𝑜𝑄 
∆𝑃𝑐 =  𝐶𝑐𝑄 
∆𝑃𝑚 =
8𝜇𝐿
𝜋𝑟4
𝑄 
Eq.4 Pressure drop terms for each subsection of the system  
 
     
Figure v. Simplified diagram of the syringe/microcatheter system with labels of the pressure 
changes expected to occur at each subsection of the system. 
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Substituting the terms in equation 2 with equations 3 and 4 reveal the following equation: 
∆𝑃𝑠𝑦𝑠 =
𝑓∗𝐹𝑛
𝜋𝑟𝑝2𝑡
+ 𝐶𝑠𝑄 + 𝐶𝑜𝑄 + 𝐶𝑐𝑄 +
8𝜇𝐿
𝜋𝑟4
𝑄 
𝑃𝑎 =
𝑓∗𝐹𝑛
𝜋𝑟𝑝2𝑡
+ 𝐶𝑠𝑄 + 𝐶𝑜𝑄 + 𝐶𝑐𝑄 +
8𝜇𝐿
𝜋𝑟4
𝑄 + 𝑃𝑓 
𝐹𝑎
𝐴
=
𝑓∗𝐹𝑛
𝜋𝑟𝑝2𝑡
+ 𝐶𝑠𝑄 + 𝐶𝑜𝑄 + 𝐶𝑐𝑄 +
8𝜇𝐿
𝜋𝑟4
𝑄 + 𝑃𝑓  
Eq.5 Pressure drop across the whole system expressed in detailed terms. 
There is the additional possibility to further simplify the equation by combining ∆Pp, ∆Ps and ∆Po into 
a combined ∆Psyr as a pressure drop across the syringe and measure a combined loss coefficient Csyr. 
Csyr would be best obtained empirically by working backwards and measuring the minimum force 
needed to move the plunger in a filled syringe open to the atmosphere. An example of such a setup 
could use a modified Harvard syringe pump with a load cell connected in series to measure the force 
exerted by the pump at a certain plunger velocity. Substituting for this, we have: 
𝐹𝑎
𝐴
= 𝐶𝑠𝑦𝑟𝑄 + 𝐶𝑐𝑄 +
8𝜇𝐿
𝜋𝑟4
𝑄 + 𝑃𝑓 
Eq.6 Simplified system pressure drop expressed in terms of applied force by the interventionalist. 
In the event that the flow deviates from ideal assumptions (i.e. non-laminar flow, can be checked by 
calculating the Reynold’s number 
𝜌𝑣𝐿
𝜇
), the more generalized Darcy-Weisbach equation can be used 
instead of Pousielle equation. If we were to also take into account the fluid velocity within the syringe 
then the application of Bernoulli’s equation and continuity equation would be more appropriate and 
the loss terms will then depend on Q2 instead of Q. Doing so would yield the following, assuming effect 
of gravity is negligible:  
𝑃𝑎 − ∆𝑃𝑝
𝜌𝑔
+
𝑉0
2
2𝑔
=
𝑃1
𝜌𝑔
+
𝑉1
2
2𝑔
+ (𝑓
𝐿
𝐷
+ Σ𝐾)
𝑉1
2
2𝑔
 
Eq.7 Darcy-Weisbach equation for calculating system pressure drop for non-ideal flow: 𝑓=Darcy friction factor, 
L=length of microcatheter, D=diameter of microcatheter, K=loss coefficients at the nozzle and connector. 
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The pressure inside the syringe is expressed by the Pa – ∆Pp and the average velocity of the fluid 
moving inside the syringe is V0. P1 and V1 denotes the pressure and velocity at the end of the 
microcatheter right before the fluid exits into the blood stream. K is the aggregate loss coefficient 
from the two step-down contractions at the syringe nozzle and at the converging connector (confuser 
geometry) to the microcatheter. It is well known from experimental studies that pressure losses at 
contractions are dependent on downstream velocity only (i.e. V1). The average velocities can be 
converted to volumetric flow rates (Q) based on the simple equation Q = VA, where V is the average 
velocity and A is the cross-sectional area. For Q0 the area of the syringe plunger is used and for Q1, the 
cross-sectional area of the inner lumen of the microcatheter is used.  
Finally, it is worth noting that the exit condition in the blood stream is dependent on the difference 
in velocity between the free stream and the catheter glue flow as well the difference in viscosity 
between the two mediums. This can be best described as a co-axial flow scenario where the outer 
shell flow consists of blood and the inner stream injected into this shell flow (also known as bulk flow) 
consists of NBCA/Lipiodol mixture. Idealized flow studies have shown an important transition from 
dripping to jetting flow depending on the difference in velocity and viscosity.[40] In the real-world 
scenario, wall interaction and polymerization (transformation from liquid to solid) during injection 
further complicates the analysis.  
The analysis above serves as a conceptual framework when considering the variables involved in 
the injection of liquid embolic agents during treatment of brain AVMs. In the present study, the 
interaction between glue, vessel wall and bulk flow will be characterized via simulated in-vivo 
injections. The remaining parts of the aforementioned analysis will not be explored due to scope 
and time constraints. The analysis lays the foundation for future work and will be part of another 
study aimed at quantifying the injection parameters during brain AVM embolization. 
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Background and objective:  
Brain arteriovenous malformations (AVMs) are abnormal connections between arteries and veins 
without an intervening capillary bed.[1, 2] Their prevalence ranges from 1 to 20 per 100,000 patients, 
and of these, approximately half will present with an intracerebral hemorrhage resulting in 
significant morbidity (30-40% per event) and mortality (10% per event).[1-6] Endovascular glue 
embolization with injection of N-butyl cyanoacrylate (NBCA) is an accepted form of treatment.[7-10] 
It is most often used as an adjunct to surgery or radiosurgery, although it can be sufficient as a 
standalone treatment in approximately 5-10% of cases.[8] In carefully selected cases the cure rate 
with endovascular embolization can be higher, ranging from 20% to 50%.[7, 11-15]  
Although ethylene vinyl alcohol copolymer (EVOH, sold by Covidien as Onyx®) has quickly become a 
preferred liquid embolic agent at many centers, there are certain high-flow AVMs (usually with 
fistulous components) where Onyx cannot be used due to the risk of passage into the venous outflow 
system. This typically results from inadequately fast polymer precipitation rate to match the AVM 
flow rate. NBCA remains a mainstay of treatment in such situations but is also associated with 
complications. Most of the complications that occur during embolization with NBCA are related to 
polymerization rate.[7, 8] A rate that is too fast may cause proximal feeding artery occlusion. Glue 
could then reflux back into normal upstream vessels, causing stroke. Conversely, a rate that is too 
slow could cause the glue to occlude the draining vein, or embolize to dural sinuses and the lung.[16-
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18] Premature venous drainage occlusion may raise the AVM intranidal pressure and trigger 
intracranial hemorrhage. [19-21]  
Existing scientific literature reports a wide range of polymerization rates with significant 
discrepancies between in-vivo and in-vitro results.[8, 22, 23] Furthermore, the interaction between 
glue and vessel surface, as well as the presence of biologic catalysts are poorly understood. Therefore, 
despite its clinical use for over 4 decades (FDA approved in 2000 with use dating almost 3 decades 
prior)[9, 10], there is still incomplete understanding of NBCA polymerization and injection 
behavior.[8] This has resulted in wide variation with respect to the degree of dilution (typically 
modified by altering glue/Lipiodol or glue/acetic-acid ratio)[24] and injection technique (sandwich, 
wedge or full-column technique) used for NBCA embolization procedures.[7, 8]   
The decreasing amount of NBCA operator experience with the introduction of Onyx coupled with the 
incomplete understanding of NBCA behavior further exacerbates treatment risk for patients, 
especially in situations where NBCA is the only option. In this study, we aim to systematically 
characterize the factors that influence NBCA polymerization in both static and dynamic 
environments. Such information could help interventionalists to optimize injection parameters and 
potentially reduce complications.  
Methods:  
From previous studies[8, 22-25] and our preliminary data, NBCA appears to behave differently in the 
presence of biological tissue compared to tissue-free vessel substitutes. NBCA interactions were 
deconstructed into three categories: influence of physical parameters (namely temperature and pH); 
physical interaction between NBCA and vessel wall (both non-biological and biological); and 
influence of exposure to biological tissue.   
The influence of pH and temperature on NBCA polymerization time was measured. The submerged 
droplet test method was employed where small droplets of NBCA (~0.1cc) were deposited on an 
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inert PVA-C surface (confirmed through preliminary work) and continuously monitored via high-
definition video recording system. The glue was kept submerged in an aqueous environment to 
simulate the physical conditions during embolization. Polymerization time was measured for 
clinically relevant mixtures of Lipiodol/NBCA of 50/50, 60/40, 70/30 ratios (NBCA was mixed with 
Lipiodol to provide radio-opacity and to delay polymerization). Polymerization times were recorded 
for solution pH values of 4, 5.5, 6.5 and 7.4 at temperature of 37.4oC. This corresponded to physiologic 
solutions of D5W, normal saline, Ringer’s lactate, and Plasma-Lyte® respectively. These solutions 
provided an aqueous acellular and plasma-free environment. Polymerization times were also 
recorded for solution temperature values of 15, 20, 25, 30, 35 and 37.5oC at pH of 7.4 (Plasma-Lyte® 
solution used).  
The physical interaction between NBCA and the vessel wall was analyzed using the contact angle 
method with the important modification of performing all measurements in a submerged aqueous 
environment. Native avian endothelium was used as the reference surface and droplets of NBCA 
(~0.1cc) were carefully placed on the flattened vessel surface using a syringe with a 25-gauge needle. 
Silicone (both plain and heparin coated) and poly-vinyl alcohol cryogel (PVA-C) surfaces were tested 
as vessel substitutes and compared to the endothelial surface. Silicone was chosen due to its ubiquity 
and its status as a “de facto” vessel substitute in numerous prior studies involving NBCA. PVA-C was 
chosen as a hydrophilic material that better replicates the physical properties of an endothelial 
surface. All tests were carried out under physiologic conditions (pH 7.4, temperature 37.5oC) in an 
acellular and plasma-free environment.  
To delineate the role of potential biological catalysts, the endovascular environment was separated 
into endothelial surface and blood products. The effect of endothelial surface was assessed by placing 
NBCA droplets on a flattened viable (<6 hours from time of harvest) endothelial surface while video-
recording the polymerization reaction. The effect of blood products was further broken down into 
plasma, platelets, packed red blood cells (RBCs), and lysed RBCs. Polymerization times were 
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measured by first placing a layer of each of the respective blood products on a PVA-C (inert) surface, 
followed by placing NBCA droplets onto the surface. All tests were performed in an aqueous 
environment at pH of 7.4 and temperature of 37.5oC. Since polymerization is a continuous process, 
polymerization times were calculated for each glue concentration at three different time points: t0, 
t50 and tc. t0 is the time from initial glue deposition to the onset of polymerization, first observed when 
the surface of the glue droplet opacifies and the droplet just begins to deform. t50 is the time to 
achieve a 50% change in height of the glue droplet (or 50% reduction in diameter in any direction). 
tc is the time to near-complete polymerization (or over 95% polymerization based on continuous 
video observation). 
Visual assessment of polymerization was performed based on video recording footages. Frame-by-
frame analysis (video recorded at standard 30fps) was performed to accurately calculate t0, t50 and 
tc times. To further confirm that near-complete polymerization had truly occurred at tc, we 
performed indentation tests on select glue droplets using an ASTM type OO indenter with a modified 
10-gram load. This allowed us to assess whether the center of the glue droplet still remained liquid 
once the outer shell had opacified.  
Finally, to examine the dynamic behavior of NBCA/Lipiodol mixture in an AVM feeding artery during 
microcatheter injection, high-speed video analysis of glue injection was performed to characterize 
flow and simulate in-vivo conditions. A flow circuit was constructed using a pulsatile pump with 
tubing connected to straight vessel substitutes made of heparin coated silicone (Medtronic, USA). 
Heparin coating improves surface hydrophilicity compared to plain silicone while providing 
transparency for high-speed video recording. A flow bypass circuit was connected parallel to the 
vessel substitute. This allowed the pressure and flow rates to be adjusted to match conditions 
typically encountered in an AVM feeder. A rotating hemostatic valve (RHV) was connected upstream 
of the vessel substitute to allow microcatheter insertion (SL-10). The dynamic behavior of 
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NBCA/Lipiodol flow within the vessel was considered akin to co-axial flow as described by Utada et 
al, with a transition from “dripping” to “jetting” as the outer shell (blood) flow increased.[26] 
At least 3 droplets were used for each glue formulation/test condition combination. Statistical 
significance was determined using a two-tailed Student’s t-test, ANOVA or chi-squared analysis 
wherever appropriate. Results are expressed as mean +/- Standard Deviation (SD). Results are 
considered significant when P < 0.05. 
Results:  
pH and Temperature: The polymerization times for three different formulations of Lipiodol/NBCA 
(referred from here on in as “glue” for simplicity) are plotted against pH and temperature in Figures 
1A and 1B respectively.  Polymerization time decreased (indicating increasing polymerization rate) 
with increasing pH as well as increasing NBCA glue concentration. Both pH and glue formulation 
independently influenced polymerization time and their effects are statistically significant based on 
2-factor ANOVA. The influence of temperature on polymerization rate is plotted in Figure 1B. 
Although the brain is at body temperature during interventional procedures, the catheters are 
constantly flushed with ambient temperature solution. As such, the AVM nidus temperature could 
actually be slightly below body temperature. As expected from reaction kinetics, increasing 
Figure 1. Polymerization time vs pH (A) and temperature (B) plots for three different mixtures of lipiodol/NBCA 
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temperature caused a corresponding increase in polymerization rate. Both temperature and glue 
formulation also independently influenced polymerization time with statistical significance (2-factor 
ANOVA).  
NBCA – Vessel Wall interactions: The submerged contact angle of glue droplets on silicone (52±3o, 
Figure 2A), heparin coated silicone (84±3o, Figure 2B) and PVA-C (150±8o, Figure 2C) were markedly 
different from each other (pairwise comparisons using two-tailed Student’s t-test all resulted in 
p<0.05). The contact angle between glue and endothelium was found to be 151±3o (Figure 2D). There 
was no statistically significant difference in contact angle between endothelial and PVA-C surfaces. 
However, the difference between the endothelial and the two silicone surfaces were significantly 
different (Figure 3). There was no statistically significant difference in contact angle for a given 
surface between various glue formulations (50/50, 60/40 and 70/30, data not shown). 
 
 
 
 
 
 
 
 
 
 
Biological Catalysts: From previous studies[8, 22-25] and our own observations, glue polymerization 
rate increases in the presence of biological tissue. Figures 4 shows time-lapse photographs of glue 
droplets (60/40 formulation) on an endothelial surface (pH=7.4, 37.5oC). Figure 5 shows glue 
droplets (60/40 formulation) on a PVA-C surface at 5 minutes after initial placement and 
Figure 2. Contact angle measurements between 
NBCA/Lipiodol and difference surfaces submerged in 
D5W at 37.5oC: silicone, silicone with heparin coating 
PVA-C and endothelium surfaces 
A. Silicone 
C. PVA-C D. Endothelium 
B. Silicone +Hepa. 
Figure 3. Contact angle measurements for silicone, 
silicone with heparin coating, PVA-C and endothelium 
surfaces 
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confirmatory indentation test to assess extent of polymerization. Glue droplets on both surfaces 
started out at t=0 seconds looking identical with similar appearances to those shown in Figure 2C 
and 2D. However, as time progressed the glue droplets on the endothelial surface started 
polymerizing from the bottom-up. This directional preference caused the droplet to flatten out over 
time with complete polymerization occurring at approximately t=90 seconds. In contrast to this, the 
glue droplets on the PVA-C surface (Figure 5) opacified and flattened somewhat initially but then 
changed very little as time went on. Indentation test was performed at t=300 seconds on glue 
droplets on the PVA-C surface. Despite the glue droplets’ optical appearance, their centers never truly 
polymerized even after 300 seconds. This was demonstrated by the blue liquid glue streak running 
between the polymerized shell and the type OO indentor tip.  
  
 
 
 
 
 
 
 
 
 
 
The decomposition of the endovascular environment yielded the following major biological 
components: endothelium, plasma, platelet and RBC. Their effect on glue polymerization time was 
further explored. Given that polymerization is a continuous process, the times to, t50 and tc were 
calculated for each glue formulation and biological substrate combination as shown in Figures 6-8. 
Figure 4. Endothelium catalyzes polymerization 
from the bottom-up, effectively flattening the 
droplet as polymerization approach tc of 
approximately 90 seconds 
Figure 5. Indentation test on PVA-C surface at t=300sec (60/50 pH 7.4) 
showing incomplete polymerization with liquid centre 
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Table 1 shows the polymerization times for glue droplets on an endothelial surface. Overall, 
polymerization times decreased as the biological substrate varied from endothelium, plasma, 
platelets, packed RBC and lysed RBC. Lysed RBC appear to result in the greatest decrease in 
polymerization time (corresponding to the greatest increase in polymerization rate) as 
demonstrated based on the measured values of to, t50 and tc.  
 
 
 
 
Plasma Platelets Packed RBC Lysed RBC
70/30 2.35 2.12 0.65 0.31
60/40 1.08 0.62 0.42 0.13
50/50 0.78 0.60 0.15 0.08
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Figure 6. The effect of plasma, platelets, packed RBC and lysed RBC on the time to onset 
of polymerization t0 for various glue formulations  
Figure 7. The effect of plasma, platelets, packed RBC and lysed RBC on the time to 
achieve 50% change in dimension of glue droplet t50 for various glue formulations  
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Table 1. Effect of endothelium (no blood products) on polymerization 
times t0, t50 and tc for various glue formulations, measured in seconds  
Glue: 50/50 Glue: 60/40 Glue: 70/30 
t0 0.6 ± 0.3 1.6 ± 0.4 13 ± 3 
t50 8 ± 2 72 ± 6 614 ± 31 
tc 98 ± 4 416 ± 6 1880 ± 68 
 
Figure 9 shows an example of polymerization time measurements for 70/30 glue formulation upon 
exposure to plasma. The glue appeared transparent upon initial deposition at t = 0 seconds. At t0 = 
2.4 seconds the glue droplet opacified and began to deform, providing a visual indication of the start 
of polymerization. At t50=7.5 seconds the glue droplet flattened to approximate 50% of the original 
height and appeared more irregular due to ongoing polymerization. Finally, at tc = 116 seconds 
polymerization was complete and the glue droplet lost its bluish hue while taking on an irregular 
multi-lobulated morphology. Figure 10 shows the exposure of 60/40 glue formulation to lysed RBC 
which resulted a very fast polymerization time. t0 occurred almost instantaneously at 0.13 seconds 
and t50 was achieved at only 1 second after glue deposition. Complete polymerization occurred after 
approximately 8 seconds with the glue cast exhibiting a similar white irregular appearance as Figure 
Plasma Platelets Packed RBC Lysed RBC
70/30 115.60 75.68 29.86 14.91
60/40 37.72 32.09 19.82 8.42
50/50 28.44 26.86 12.25 7.56
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Figure 8. The effect of plasma, platelets, packed RBC and lysed RBC on the time to 
achieve near-complete (>95%) polymerization tc for various glue formulations  
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9. The polymerization time was so rapid that the NBCA droplet did not have sufficient time to detach 
from the depositing needle, polymerizing at the tip.  
 
 
 
 
In Vivo Simulation: Figure 11 illustrates the idealized model of coaxial flow as previously described 
by Utada et al. The outside shell flow is akin to the blood flow in an AVM feeding artery while the 
central coaxial flow mimics the microcatheter glue injection. As the injection rate increased, there 
appeared to be a transition from dripping to jetting flow.[26] Figure 12 shows the experimental 
observations (recorded at 240fps), where three distinct phases are noted. Phase 1 (12A) consisted 
of dribble flow that lasted only 1-2 seconds before the whole microcatheter was filled with NBCA. 
Phase 2 (12B) continued as jetting flow (short jet) with length of jet dependent on outer shell flow 
velocity and vessel diameter. Phase 3 (7C) occurred when NBCA wetted the vessel wall and continued 
to roll off the vessel wall, sending droplets downstream so long as the glue remained liquid. Phase 3 
was not described by Utada et al.8 since their model assumed the injection catheter to be in the middle 
of the vessel, free from any wall-effect. Based on our observations, during endovascular 
microcatheter injections, it is more common to have the microcatheter tip against the wall or pointed 
at an angle towards the wall.  
Figure 10. t0, t50, and tc times for 60/40 glue 
formulation during exposure to lysed RBCs 
Figure 9. t0, t50, and tc times for 70/30 glue formulation 
during exposure to plasma 
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Discussion: 
In this study, we sought to systematically characterize the factors that influence NBCA 
polymerization in both static and dynamic environments. The effect of pH and temperature on glue 
polymerization time is known. However, a detailed quantification of their effect on glue 
polymerization has not been previously reported. Exposure to anions is the most common way to 
initiate polymerization in cyanoacrylates. Anions act as electron donors to initiate the reaction. Once 
initiation occurs, chain propagation will continue spontaneously for variable lengths.[27] The 
hydroxide (OH-) anion is ubiquitous in aqueous environments, present whenever there is H2O. In the 
clinical setting, prior to glue injection the microcatheter is thoroughly flushed with D5W (5% 
dextrose solution) with the common explanation that D5W does not contain any ions. From a basic 
chemistry stand point, this is false since all solutions will contain ions. It is the relative concentration 
of these ions that will influence polymerization time, and D5W happens to be the most acidic isotonic 
solution used clinically with a pH of 4. This translates to the lowest concentration of OH- groups 
available of any solution, resulting in the best prevention against polymerization. 
The physical interaction of glue with different surfaces provides some caution in interpreting in-vitro 
flow studies in existing scientific literature. Silicone is often used as a de-facto vessel substitute in 
flow models. However, the behavior of glue on silicone is quite different from that of endothelium. 
Figure 11. Coaxial flow 
model[26] 
Figure 12. Screenshots of high speed video analysis of NBCA injection 
illustrating an initial period of dribbling flow (A, <1sec) followed by short 
jetting flow (B, 1-2 sec). Wall-effect eventually takes over (C) at variable 
time point depending on microcatheter position (typically starting at 
approximately 3 seconds). 
A 
B 
C 
 Page | 29  
 
Glue tends to spread more easily and stick to a silicone surface more readily, effectively “coating” it 
due to the shallow contact angle. This reduces glue flow velocity compared to the average bulk flow 
velocity and gives glue more time to polymerize in the silicone tubing. Therefore, studies employing 
silicone flow models to study glue embolization may over-estimate the effect of glue polymerization 
(especially in the absence of any biological tissue) in achieving flow arrest.[28]  
As a mock vessel surface, PVA-C provided the closest mimicry of endothelium. However, due to the 
lack of any catalytic activity, it was paradoxically more difficulty to achieving flow arrest when 
injecting glue into PVA-C tubing. During polymerization, glue would form strong chemical bonds with 
the endothelial surface (based on our observations) that could act as anchor points. Glue did not bond 
to PVA-C readily, further exacerbating the flow arrest problem. In-vitro studies that employ mock 
vessels with hydrophilic surfaces should be interpreted in light of these findings.  
The effects of biological substrates on glue polymerization time is significant and may help explain 
some of the discrepancies in previous studies that measured the polymerization time of NBCA in the 
in-vitro setting. In one of the earliest papers, Stoesslein et al. measured the in-vitro polymerization 
rate of NBCA/Lipiodol mixtures by bringing it into contact with citrated blood on a cover glass slip 
and visually observing polymerization.[24] The authors did not further specify the criteria used to 
judge polymerization, although the values that they published appeared closer to tc. Brothers et al. 
used a very different in-vitro method where glue droplets were dripped into human plasma held in 
a transparent cup with a piece of newspaper underneath it.[23] Opacification of the newspaper 
letters was defined as polymerization time, which is likely in between t0 and t50. Interestingly, both 
authors noted that in-vivo studies seemed to result in faster polymerization times compared to in-
vitro results.  
A few explanations were entertained to explain the in-vitro/in-vivo discrepancy, such as mixing 
caused by bulk flow of blood and the greater availability of anions in-vivo. In light of the results of 
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this study, it was fortuitous that Stoesslein et al. used whole blood as a biologic catalyst (albeit 
unknowingly). However, their values were closer to tc (3.2, 4.7 and 7.5 seconds for 50/50, 33/66 and 
25/75 formulations respectively) than t50 since they were measuring near-complete polymerization. 
Brothers et al. on the other hand used plasma, which would give a slower polymerization rate. 
However, they chose opacification as the polymerization end point which occurs quite early as seen 
in Figures 4, 5, 9 and 10. This provided partial offset to the slower polymerization time in plasma and 
the study ended up with values (0.7, 2.5, 3 and 4 seconds for 100/0, 50/50, 33/66 and 25/75 
formulations respectively) that were closer to t50 in pRBC.  
In the in-vivo setting, glue polymerization cannot be measured directly, and operators must use other 
clues such as nidus penetration or flow arrest as surrogate measures. This depends not only on 
polymerization time, but also on nidus morphology. Polymerization times may seem faster in-vivo 
for two reasons: 1. The presence of biologic substrates (especially RBCs) and 2. Interference from 
nidus or proximal feeders that allows partially polymerized glue to change/block flow before tc is 
reached. It is for the second reason that we measured not only tc, but also t0 and t50. Looking at the 
values of t50, they appear to better approximate the time scales encountered clinically during 
embolization of AVMs (where contrast filling of the nidus can occur as quickly as 0.25 – 0.5 seconds). 
Glue does not need to fully polymerize to exert its effect, it just has to be hard enough to plug part of 
the nidus or feeding artery for stasis to occur.  
Exposure to lysed RBC appears to result in the fastest glue polymerization time. The exact reason for 
this is unknown. It is known that amine groups from proteins can act as electron donors to initiate 
polymerization via a zwitterionic mechanism.[27] Cyanoacrylates have also been shown to form 
covalent bond with proteins (i.e. protein adducts) upon exposure to biologic tissue.[29] Cell 
membrane components and charge probably do not fully explain this since both endothelium and 
platelets contain cell membranes and neither substrate showed polymerization times that were as 
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rapid. Proteins and dissolved ions in general do not fully explain this either, since plasma contain 
abundant quantities of proteins (coagulation factors, immunoglobulins, albumin, etc.) and ions but 
does not have as rapid a polymerization time. Since lysed RBCs resulted in even faster polymerization 
rates than whole RBCs, this leads us to surmise that RBC-specific intracellular content plays the 
biggest role, and hemoglobin is highly suspect. More work will be needed to further delineate this. 
High-speed video analysis of microcatheter glue injection revealed that unlike the idealized flow 
model, wall interaction is an important factor to consider. Wall interaction causes smearing and 
sticking of liquid glue with possible formation of anchor points after polymerization occurs. The 
heparin coated silicone surface provides good light transparency but does not provide the same 
degree of hydrophilicity as endothelium. The smearing will likely be less prominent in an 
endothelial surface. However, endothelium does have some degree of catalytic activity and also 
bonds to NBCA very well. Therefore, premature feeding artery occlusion is still a concern even with 
a well-adjusted glue formulation. A partially formed adherent glue cast in the proximal feeder (due 
to the wall-effect) could trigger more glue adhesion and polymerization, resulting in feeding artery 
occlusion before the nidus is fully embolized. One of the best ways to mitigate this problem is to 
navigate the microcatheter as close to the nidus as possible, with the wedge technique being an 
extreme example of this. Both the sandwich and full-column technique will be subject to wall-effect 
if the microcatheter tip is parked in the proximal feeding artery some distance away from the nidus.  
 
Conclusion:  
We have successfully deconstructed the dynamic behavior of NBCA embolization into its components 
to allow for better characterization of polymerization and injection parameters. PVA-C provides a 
better vessel substitute with respect to physical surface properties; however, it does not possess any 
catalytic activity encountered in the in-vivo setting. Biological catalysts play a substantial role in 
increasing polymerization rate with exposure to RBCs being the most important factor. Clinically 
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relevant polymerization times likely fall somewhere closer to t50 than to tc which may help optimize 
glue formulation selection. Clinically, continuous flushing of the microcatheter with D5W provides 
an acellular/plasma-free environment with the lowest pH to prevent unanticipated early 
polymerization which is most likely related to contamination with RBC’s. High-speed video analysis 
reveals that microcatheter injection exhibits dripping to jetting transition with an important 
additional phase of vessel wall interaction. A refined understanding of the polymerization behavior 
of NBCA could help reduce embolization-related complications.  
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Appendix I 
Onyx static droplet test 
Droplet injection tests were performed for Onyx for comparison. The precipitation of Onyx appears 
to be very different from the polymerization of NBCA (Figure s1). Onyx has higher viscosity than 
Lipiodol/NBCA mixture and flows out of the syringe like a viscoelastic material rather than a liquid. 
The outer shell appears to precipitate first and solidify into a semi-soft solid within 1-2 seconds and 
no further outward indication of precipitation can be observed. Further injection results in liquid 
Onyx flowing between the formed cast and the vessel surface, with progressive widening of the 
base. Newly injected Onyx appear to adhere to existing precipitated Onyx. The center portion 
remains liquid for a significantly longer period of time and can be seen from the Onyx streaking 
upon withdraw of the 25-gauge syringe needle. There is no significant correlation between pH and 
precipitation rate. There is also no significant difference between silicone, PVA-C and endothelial 
surfaces. The presence of endothelium does not appear to increase the precipitation rate. The effect 
of blood on Onyx precipitation rate was not investigated.   
 
 
 
Figure s1. Injection of Onyx on endothelium (pH 7.4, temp 37.5oC). The method used for the 
assessment of NBCA polymerization time with t0, t50, and tc cannot be applied here. The panel 
from left to right show injection times of 0, 3, 15 and 30 seconds respectively with injection been 
slowly and continuously performed for 15 seconds. No adhesion to endothelium was observe and 
no outward evidence of continuing precipitation can be appreciated. The center still appear liquid 
based on streaking from needle tip in the last frame. 
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Appendix II 
Statistical Analysis 
Polymerization time vs. temperature 
Anova: Two-Factor Without Replication     
       
SUMMARY Count Sum Average Variance   
15C 3 208.97 69.65667 2434.973   
20C 3 216.6 72.2 600.33   
25C 3 171.63 57.21 404.7933   
30C 3 127.5 42.5 275.25   
35C 3 88.67 29.55667 149.2196   
37.5C 3 73.67 24.55667 66.28963   
       
50/50 6 186.1 31.01667 207.1257   
60/40 6 262.3 43.71667 246.9817   
70/30 6 438.64 73.10667 1229.367   
       
       
ANOVA       
Source of Variation SS df MS F P-value F crit 
Temperature 6148.924 5 1229.785 5.421256 0.011396 3.325835 
Glue formulation 5593.26 2 2796.63 12.32837 0.002 4.102821 
Error 2268.45 10 226.845    
       
Total 14010.63 17         
 
 
 
Polymerization time vs. pH  
Anova: Two-Factor Without Replication     
       
SUMMARY Count Sum Average Variance   
pH 4 3 946.666 315.5553 15890.82   
pH 5.5 3 875.667 291.889 28537.31   
pH 6.5 3 668.333 222.7777 33306.48   
pH 7.4 3 535 178.3333 22533.33   
       
50/50 4 363 90.75 5541.196   
60/40 4 1048.333 262.0833 4717.37   
70/30 4 1614.333 403.5833 3056.909   
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ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Solution pH 35733.17 3 11911.06 16.96229 0.002463 4.757063 
Glue formulation 196322.6 2 98161.32 139.7895 9.27E-06 5.143253 
Error 4213.249 6 702.2081    
       
Total 236269.1 11         
       
 
T0 Anova: Two-Factor Without Replication    
       
SUMMARY Count Sum Average Variance   
Endothelium 3 14.87033 4.956778 45.7889   
Plasma 3 4.2065 1.402167 0.694168   
Platelets 3 3.344833 1.114944 0.760792   
Packed RBC 3 1.226833 0.408944 0.062517   
Lysed RBC 3 0.520333 0.173444 0.015471   
       
70/30 5 18.18683 3.637367 26.73539   
60/40 5 3.807 0.7614 0.31687   
50/50 5 2.175 0.435 0.091528   
       
       
ANOVA       
Source of Variation SS df MS F P-value F crit 
Biologic 44.98624 4 11.24656 1.414908 0.312643 3.837853 
Formulation 31.05479 2 15.52739 1.953472 0.203779 4.45897 
Error 63.58891 8 7.948614    
       
Total 139.6299 14         
 
 
T50 Anova: Two-Factor Without Replication    
       
SUMMARY Count Sum Average Variance   
Endothelium 3 693.861 231.287 110564.3   
Plasma 3 15.4835 5.161167 4.551478   
Platelets 3 13.22633 4.408778 2.044485   
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Packed RBC 3 7.466 2.488667 3.051579   
Lysed RBC 3 3.452167 1.150722 0.851507   
       
70/30 5 633.2078 126.6416 74062.98   
60/40 5 84.474 16.8948 958.1489   
50/50 5 15.80717 3.161433 9.804643   
       
       
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Biologic 124774.7 4 31193.68 1.423159 0.310298 3.837853 
Formulation 45800.5 2 22900.25 1.044785 0.395248 4.45897 
Error 175349 8 21918.62    
       
Total 345924.2 14         
 
 
Tc Anova: Two-Factor Without Replication     
       
SUMMARY Count Sum Average Variance   
Endothelium 3 2393.617 797.8723 902710.6   
Plasma 3 181.763 60.58767 2291.283   
Platelets 3 134.621 44.87367 718.44   
Packed RBC 3 61.938 20.646 78.03726   
Lysed RBC 3 30.89267 10.29756 16.1576   
       
70/30 5 2115.551 423.1102 664403   
60/40 5 514.0825 102.8165 30785.51   
50/50 5 173.198 34.6396 1339.752   
       
       
ANOVA       
Source of Variation SS df MS F P-value F crit 
Biologic 1404727 4 351181.7 2.033793 0.182308 3.837853 
Formulation 430242.7 2 215121.3 1.245829 0.338052 4.45897 
Error 1381386 8 172673.3    
       
Total 3216356 14         
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T0 for Lysed RBC - Anova: Single Factor     
       
SUMMARY       
Groups Count Sum Average Variance   
50/50 2 0.159 0.0795 0.000365   
60/40 3 0.379 0.126333 0.00146   
70/30 2 0.629 0.3145 0.011705   
       
       
ANOVA       
Source of Variation SS df MS F P-value F crit 
Between Groups 0.063786 2 0.031893 8.510631 0.036208 6.944272 
Within Groups 0.01499 4 0.003747    
       
Total 0.078775 6         
 
 
T50 for Lysed RBC - Anova: Single Factor    
       
SUMMARY       
Groups Count Sum Average Variance   
50/50 2 0.91 0.455 0.025992   
60/40 3 2.399 0.799667 0.005204   
70/30 2 4.395 2.1975 0.007565   
       
       
ANOVA       
Source of Variation SS df MS F P-value F crit 
Between Groups 3.511661 2 1.75583 159.7474 0.000153 6.944272 
Within Groups 0.043965 4 0.010991    
       
Total 3.555626 6         
 
 
Tc for Lysed RBC - Anova: Single Factor     
       
SUMMARY       
Groups Count Sum Average Variance   
50/50 2 15.114 7.557 2.455328   
60/40 3 25.271 8.423667 3.199674   
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70/30 2 29.824 14.912 0.021632   
       
       
ANOVA       
Source of Variation SS df MS F P-value F crit 
Between Groups 67.64023 2 33.82011 15.24062 0.013457 6.944272 
Within Groups 8.876309 4 2.219077    
       
Total 76.51653 6         
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